Commercial strategy

Patient-based forecasting for biotech and pharma

We build forecasts from the patients who could actually receive a therapy, with every assumption visible and open to challenge.

What we do

A forecast is only as good as the population underneath it. We start with incidence and prevalence, then narrow to the patients who are diagnosed, staged, biomarker-positive, eligible and treated in the relevant line of therapy. Each step has a source and a date.

On top of that population we model adoption, share, treatment duration and price. We show base, upside and downside cases, and the conditions that would make each one true.

Before NextIndication, our team built epidemiology models across 12 oncology projects and patient-based forecasts for more than ten oncology assets.

How it works

Four steps, nothing hidden.

  1. 1

    Frame

    Agree the decision, the asset profile and the geography before any modelling.

  2. 2

    Size

    Build the patient flow from incidence to treated patients, with sources.

  3. 3

    Forecast

    Add adoption, share, duration and price, then build the three cases.

  4. 4

    Hand over

    You keep the workbook, the assumption register and the documentation.

Questions teams ask

Before you start.

What is a patient-based forecast?

It is a forecast built from the number of patients, not from past sales. It starts with how many people have the disease and works down to those who are diagnosed, eligible and treated, then applies market share and price.

How is it different from a top-down forecast?

A top-down forecast takes a share of an existing market value. A patient-based forecast shows who is counted at each step, so a reviewer can challenge one assumption instead of the final number.

Can you review a forecast we already have?

Yes. We review the logic, overrides and sources of an existing model, rank the issues by impact and return a corrected workbook with documentation.